微信扫一扫
实时资讯全掌握
|
A biotech firm is currently experiencing high growth and pays no dividends. One of their product patents is scheduled to expire in 5 years. This firm would be a good candidate for which of the following valuation models? A. Single-stage free cash flow to equity (FCFE). B. Two-stage free cash flow to equity (FCFE). C. Two-stage dividend discount model (DDM). |